Signaling in Inflammation Laboratory, Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Signaling in Inflammation Laboratory, Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Biomed Pharmacother. 2021 Jan;133:111033. doi: 10.1016/j.biopha.2020.111033. Epub 2020 Dec 8.
For decades, glucocorticoids (GC) have been used to treat several inflammatory conditions, including chronic and autoimmune diseases, due to their potent anti-inflammatory properties. In the context of infectious diseases, the use of GCs may be effective as adjuvant to antibiotic therapy by controlling excessive inflammatory responses resulting in better outcome in some cases. However, the use of GCs has been associated with a vast number of side effects, including increased probability of immunosuppression and consequent risk of opportunistic infection. Glucocorticoid-induced leucine zipper (GILZ) and Annexin A1 (AnxA1) are GC-induced proteins intrinsically involved with the anti-inflammatory functions of GCs without the associated adverse metabolic effects. Recent studies have shown that these GC-proteins exhibit pro-resolving effects. An essential characteristic of pro-resolving molecules is their ability to coordinate the resolution of inflammation and promote host defense in most experimental models of infection. Although the role of GILZ and AnxA1 in the context of infectious diseases remain to be better explored, herein we provide an overview of the emerging functions of these GC-proteins obtained from pre-clinical models of infectious diseases.
几十年来，由于糖皮质激素（GC）具有强大的抗炎特性，因此被用于治疗多种炎症性疾病，包括慢性和自身免疫性疾病。在传染病方面，GC 的使用可能通过控制过度的炎症反应而与抗生素治疗联合使用在某些情况下更有效，从而获得更好的结果。然而，GC 的使用与大量副作用相关，包括增加免疫抑制的可能性和随之而来的机会性感染的风险。糖皮质激素诱导的亮氨酸拉链（GILZ）和膜联蛋白 A1（AnxA1）是 GC 诱导的蛋白，它们内在地参与 GC 的抗炎功能，而没有相关的不良代谢作用。最近的研究表明，这些 GC 蛋白具有促解决作用。促解决分子的一个重要特征是它们能够协调炎症的解决，并在大多数感染的实验模型中促进宿主防御。尽管 GILZ 和 AnxA1 在传染病中的作用仍有待进一步探索，但本文综述了从传染病的临床前模型中获得的这些 GC 蛋白的新兴功能。
